The role of p53, pRb, p21WAF1/CIP1, PCNA, mdm2 and cyclin D1 in regulation of cell cycle and apoptosis;Rola białka p53, pRb, p21WAF1/CIP1, PCNA, mdm2 oraz cykliny D1 w regulacji cyklu komórkowego oraz apoptozy

Onkologia Polska

Volumn 8, Issue 4, 2005, Pages 223-228

  Dworakowska, Dorota ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Apoptosis; Cell cycle

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL PROTECTION; GENE ACTIVATION; HUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTO ONCOGENE; REVIEW; STATISTICAL SIGNIFICANCE;

EID: 33644957986     PISSN: 15056732     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Schafer K.A.: The cell cycle: a review. Vet. Pathol. 1998, 35, 461-478.
2. Gerl R., Vaux DL.: Apoptosis in the development and treatment of cancer. Carcinogenesis 2005, 26, 263-270.
3. Zabel M.: Immunocytochemia. PWN. Warszawa 1999, 218-226.
4. Graziano S.L.: Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 1997, 17, supl. 1, S37-58.
5. Krzakowski M.: Onkologia kliniczna. Borgis, Warszawa 2000, 202-228.
6. Sionov R.V., Haupt Y.: The cellular response to p53: the decision between life and death. Oncogene 1999, 18, 6145-6157.
7. Prives C., Hall P.A.: The p53 pathway. J. Pathol. 1999, 187, 112-126.
8. Piette J., Neel H., Marechal V.: Mdm2: keeping p53 under control. Oncogene 1997, 15, 1001-1010.
9. Knudson AG. Jr: Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 1971, 68, 820-823.
10. Cordon-Cardo C.: Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol. 1995, 147, 545-560.
11. Levine A.J.: p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
12. Nataraj A.J., Trent J.C. 2nd, Ananthaswamy H.N.: p53 gene mutations and photocarcinogenesis. Photochem. Photobiol. 1995, 62, 218-230.
13. Sherr C.J.: Cancer cell cycles. Science 1996, 274, 1672-1677.
14. Howes K.A., Ransom N., Papermaster D.S. i wsp.: Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev. 1994, 8, 1300-1310.
15. el-Deiry W.S., Tokino T., Velculescu V.E. 1 wsp.: WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75, 817-825.
16. Dotto G.P.: p21 (WAF1/Cip1): more than a break to the cell cycle? Biochim. Biophys. Acta 2000, 1471, M43-56.
17. Li R., Waga S., Hannon G.J. i wsp.: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994, 371, 534-537.
18. Roninson I.B.: Oncogenic functions of tumour suppressorp 21 (Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002, 179, 1-14.
19. Papandreou C.N., Bogenrieder T., Loganzo F. i wsp.: Expression and sequence analysis of the p21 (WAF1/CIP1) gene in renal cancers. Urology 1997, 49, 481-486.
20. Macleod K.F., Sherry N., Hannon G. i wsp.: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995, 9, 935-944.
21. Esposito V., Baldi A., Tonini G. i wsp.: Analysis of cell cycle regulator proteins in non-small cell lung cancer. J. Clin. Pathol. 2004, 57, 58-63.
22. Bravo R., Frank R., Blundell P.A., Macdonald-Bravo H.: Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987, 326, 515-517.
23. Morris G.F., Bischoff JR., Mathews MB.: Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc. Natl. Acad. Sci. USA 1996, 93, 895-899.
24. Wiethege T., Voss B. Muller K.M.: Detection of MDM2-proto-oncogene in paraffin embedded human bronchial epithelium. J. Cancer Res. Clin. Oncol. 1994, 120, 252-255.
25. Momand J., Zambetti G.P.: Mdm-2: "big brother" of p53. J. Cell. Biochem. 1997, 64, 343-352.
26. Haines D.S., Landers J.E., Engle L.J., George D.L.: Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell. Biol. 1994, 14, 1171-1178.
27. Zacharatos P.V., Gorgoulis V.G., Kotsinas A. i wsp.: Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1. Anticancer Res. 1999, 19, 579-587.
28. Akervall J.A., Michalides R.J., Mineta H. i wsp.: Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin Dl overexpression. Cancer 1997, 79, 380-389.
29. Serrano M., Hannon G.J., Beach D.: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366, 704-707.
30. Sellers W.R., Kaelin W.G. Jr: Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol. 1997, 15, 3301-3312.
31. Donnellan R., Chetty R.: Cyclin D1 and human neoplasia. Mol. Pathol. 1998, 51, 1-7.
32. Keyomarsi K., Pardee A.B.: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. Natl. Acad. Sci. USA 1993, 90, 1112-1116.
33. Zukerberg L.R., Yang W.I., Arnold A., Harris N.L.: Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. Am. J. Clin. Pathol. 1995, 103, 756-760.
34. Kerr J.F., Winterford CM., Harmon B.V.: Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994, 73, 2013-2026.
35. Soini Y., Paakko P., Lehto V.P.: Histopathological evaluation of apoptosis in cancer. Am. J. Pathol. 1998, 153, 1041-1053.
36. Hsieh J.K., Chan F.S., O'Connor D.J. i wsp.: RB regulates the stabillty and the apoptotic function of p53 via MDM2. Mol. Cell. 1999, 3, 181-193.
37. Singhal S., Vachani A., Antin-Ozerkis D. i wsp.: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin. Cancer Res. 2005, 11, 3974-3986.